Investors

Press Releases

 
Press Releases
  Date Title View
May 22, 2017
Eleven Abstracts Selected for Presentation, Including Four Highlighting Pharmacokinetic and Global Surveillance Data for Eravacycline TP-6076 Phase 1 Single-Ascending Dose Data Selected for Oral Presentation; TP-271 Phase 1 Single-Ascending Dose Data to be Featured in Poster Presentation WATERTOWN, Mass., May 22, 2017 (GLOBE NEWSWIRE) --  T...
May 4, 2017
WATERTOWN, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2017 and provided an overview of recent ac...
Apr 21, 2017
WATERTOWN, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced seven data presentations at the 27th European Congress of Clinical Microbiology and Infectious ...
Apr 3, 2017
Accelerated Timelines for Both Top-line IGNITE4 Eravacycline Data and MAA filing in Europe; Both Now Expected in 3Q 2017   IGNITE4 Results to Support U.S. NDA Filing for IV Eravacycline in cIAI  WATERTOWN, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company dev...
Mar 30, 2017
WATERTOWN, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that its pipeline candidate TP-6076 was selected to receive $4 million in research funding from...
Mar 27, 2017
WATERTOWN, Mass., March 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 16th Annual Needham Healthcare...
Mar 8, 2017
-Event-Driven 2017 Includes MAA Filing for IV Eravacycline in Europe and Top-Line Data Readout from IGNITE4 in cIAI - - Company to Host Conference Call Today, March 8, 2017 at 4:30 p.m. ET - WATERTOWN, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing ...
Mar 6, 2017
WATERTOWN, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 29th Annual ROTH Conference on...
Mar 3, 2017
WATERTOWN, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth quarter and full year 2016 financial results after t...
Jan 17, 2017
WATERTOWN, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company's phase 3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem in complicated urinary tract infections (cUTI).  Eravac...
1
...
NextLast
= add release to Briefcase